Chinese medicine stocks are hot again, and low-priced Chinese medicine stocks are worth noting!
Policy support and opportunities for the development of traditional Chinese medicine.
Recently, the ** Chinese Medicine Bureau once again proposed to increase efforts to promote the development of the Chinese medicine industry. The state has successively formulated a number of policies and measures to support the development of traditional Chinese medicine, such as the Action Plan for the High-quality Development of the Medical Device Industry, the Special Provisions on the Registration and Management of Traditional Chinese Medicine, and the Implementation Plan for Major Projects for the Revitalization and Development of Traditional Chinese Medicine, including the Action Plan for the High-quality Development of the Pharmaceutical Industry and the Action Plan for the High-quality Development of the Medical Device Industry. The state's support and support for the traditional Chinese medicine industry has created favorable conditions for the development of the traditional Chinese medicine industry.
In addition, the growth of the Chinese medicine industry is largely due to the increase in sales. When the operating efficiency is improved and the internal operating efficiency is improved, it is expected that the sales performance of the Chinese patent medicine company will be better. In addition, due to the high stability of proprietary Chinese medicines in the market, the sustainable development of the industry is also very necessary. Some people say that the Chinese medicine industry is an industry with distinct Chinese characteristics, and with the introduction of the "Chinese local value" system, its value will gradually become rationalized. As a result, the entire TCM industry will enter an upward cycle, bringing new development opportunities and value restoration to TCM companies.
It is recommended that the high-performance pharmaceutical category is lower.
According to the data, the current listed companies are below 10 yuan, and the net profit growth in the third quarter is more than 10%. These 7 companies include: Kangenbei, Yabao Pharmaceutical, Shanghai Kaibao, Guizhou Bailing, Renhe, Essence Pharmaceutical, and Jiaying Pharmaceutical. Judging from the data in the third quarter, the first place is Kangenbei, whose net profit in the first half of the year was 62.3 billion, an increase of 171 over the same period last year76%；In the third quarter, it reached 10.7 billion, an increase of 532 over the same period last year29%。In second place is Yabao Pharmaceutical, which reported a net profit of 214 percentage points, an increase of 100 over the same period last year11%。
Kangenbei said that the company's main business products such as OTC drugs such as intestinal Yanning series, vitamin C series and other health products and Chinese patent medicine products increased sales this year, which is also an important factor in its high performance. Yabao Pharmaceutical said that the company's net profit has also increased rapidly due to the increase in sales of high-hair products such as Ding Guier's belly button stickers in the quarter.
In addition to Kangenbei and Yabao Pharmaceutical, Shanghai Kaibao, Guizhou Bailing and other companies have achieved a net profit increase of more than 30%. Shanghai Kaibao Group is an international pharmaceutical company, integrating R&D, production and sales, with strong international competitiveness. Guizhou Bailing*** is the largest Miao medicine manufacturer in the field of R&D, production and sales of Miao medicine in China.
In addition, small and medium-sized companies with good performance, such as Renhe Pharmaceutical, Essence Pharmaceutical, and Jiaying Pharmaceutical, have performed well in the past year. Renhe Pharmaceutical is a leading enterprise in the domestic over-the-counter drug industry, with Chinese and Western medicines, APIs and health care products as its main business direction.
Personal Summary. On the whole, with China's strong support for the traditional Chinese medicine industry, the traditional Chinese medicine industry is entering a new period of development. The state's support for the cause of traditional Chinese medicine has been increasing, which has created favorable conditions for the development of traditional Chinese medicine. At the same time, the sales of the traditional Chinese medicine industry have been increasing, and the pricing of traditional Chinese medicine products has stabilized, which has led to the steady development of the traditional Chinese medicine industry. At the same time, since the Chinese medicine industry itself is a Chinese, under the application of the "Chinese" evaluation system, the quality assessment of the Chinese medicine industry will tend to be rationalized.
The high yields of high-quality and inexpensive Chinese herbal medicines**, such as Kangenbei and Yabao Pharmaceutical, highlight the huge prospects for the development of the TCM industry. Due to its unique advantages in product marketing, research and development, it is expected to achieve greater results in industrial development and market competition.
On the whole, the traditional Chinese medicine industry is an industry with great vitality and development prospects. Policy support and the increase in market demand have provided new development opportunities for traditional Chinese medicine enterprises. However, when selecting a traditional Chinese medicine company**, it is necessary to carefully analyze and evaluate its operating conditions and future development trends to reduce its investment risk. The author hopes that these materials can bring some enlightenment to the majority of readers.